Tuberculosis natural history, complications and prognosis
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Drug-Susceptible and Drug-Resistant Tuberculosis(ATS 2025 Guidelines) |
|
Case Studies |
|
Tuberculosis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Tuberculosis natural history, complications and prognosis |
|
FDA on Tuberculosis natural history, complications and prognosis |
|
CDC on Tuberculosis natural history, complications and prognosis |
|
Tuberculosis natural history, complications and prognosis in the news |
|
Blogs on Tuberculosis natural history, complications and prognosis |
|
Risk calculators and risk factors for Tuberculosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2];Sophia Saad, Associate Editor - WikiDoc [3] João André Alves Silva, M.D. [4]
Tuberculosis Natural History, Complications, and Prognosis
Natural history
Latent tuberculosis infection (LTBI)
In the absence of treatment, approximately 5% to 15% of immunocompetent persons with LTBI progress to active TB disease over a lifetime, with estimates varying by source (ATS/IDSA/CDC diagnostic guideline estimates 4%–6%; USPSTF cites 5%–10%; NEJM review cites 5%–15%).Lewinsohn DM, Leonard MK, LoBue PA; et al. (2016). "Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children". Clinical Infectious Diseases. doi:10.1093/cid/ciw694. PMID 27932390.US Preventive Services Task Force, Mangione CM, Barry MJ; et al. (2023). "Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement". JAMA. doi:10.1001/jama.2023.4899. PMID 37129649 Check |pmid= value (help).Shah M, Dorman SE (2021). "Latent Tuberculosis Infection". The New England Journal of Medicine. doi:10.1056/NEJMcp2108501. PMID 34879449 Check |pmid= value (help).
People with untreated HIV infection have an estimated annual risk of progression to TB disease of 3% to 16%."Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV". NIH Office of AIDS Research Advisory Council. 2025.
Untreated active tuberculosis
Untreated active TB can progress over weeks to months with ongoing tissue destruction and increased transmission risk (for pulmonary disease). Pre-chemotherapy era systematic reviews provide the following estimates for HIV-negative individuals: untreated smear-positive pulmonary TB has a 10-year case fatality of approximately 70% (weighted mean), while culture-positive, smear-negative TB has an estimated 10-year case fatality of approximately 20%.Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ (2011). "Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review". PLoS One. doi:10.1371/journal.pone.0017601. PMID 21483732.
The average duration of untreated pulmonary TB from onset to cure or death is approximately 3 years.Ragonnet R, Flegg JA, Brilleman SL; et al. (2021). "Revisiting the Natural History of Pulmonary Tuberculosis: A Bayesian Estimation of Natural Recovery and Mortality Rates". Clinical Infectious Diseases. doi:10.1093/cid/ciaa602. PMID 32766718 Check |pmid= value (help).
In children (pre-treatment era), case fatality was 44% in those aged 0–4 years and 15% in those aged 5–14 years.Jenkins HE, Yuen CM, Rodriguez CA; et al. (2017). "Mortality in Children Diagnosed With Tuberculosis: A Systematic Review and Meta-Analysis". The Lancet Infectious Diseases. doi:10.1016/S1473-3099(16)30474-1. PMID 28100428.
Complications
Pulmonary complications
Common pulmonary complications include:
Cavitation Hemoptysis (including massive hemoptysis; e.g., Rasmussen's aneurysm) Pneumothorax Empyema Bronchiectasis / post-infectious airway disease Acute respiratory distress syndrome (ARDS) (uncommon; more likely with severe disseminated disease)Dheda K, Barry CE, Maartens G (2016). "Tuberculosis". Lancet. doi:10.1016/S0140-6736(15)00151-8. PMID 26842682.
Extrapulmonary and disseminated complications
Miliary tuberculosis and other disseminated forms (hematogenous spread).Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003). "Tuberculosis". Lancet. doi:10.1016/S0140-6736(03)14333-4. PMID 13678977. Site-specific complications may include neurologic disability from tuberculous meningitis, pericardial complications (effusion/constriction), skeletal deformity from spinal TB, and infertility/obstructive uropathy from genitourinary TB.
Post-tuberculosis sequelae (after microbiologic cure)
Risk factors associated with post-TB sequelae have been summarized in systematic review and meta-analysis.Akalu TY, Clements ACA, Liyew AM; et al. (2024). "Risk Factors Associated With Post-Tuberculosis Sequelae: A Systematic Review and Meta-Analysis". EClinicalMedicine. doi:10.1016/j.eclinm.2024.102898. PMID 39402872 Check |pmid= value (help).
Quantitative estimates of post-TB lung disease (PTLD) burden include: approximately 50% of pulmonary TB survivors have abnormal spirometry at or after treatment completion, with severe impairment in 10%–15%; bronchiectasis is observed in 35%–86% on imaging.Meghji J, Auld SC, Bisson GP; et al. (2025). "Post-Tuberculosis Lung Disease: Towards Prevention, Diagnosis, and Care". The Lancet Respiratory Medicine. doi:10.1016/S2213-2600(24)00429-6. PMID 39971252 Check |pmid= value (help).
Chronic pulmonary aspergillosis (CPA) prevalence in TB survivors ranges from 7% to 23%, with residual cavitation being the strongest risk factor (annual incidence of new CPA ~6.5% in those with cavitation vs 0.2% without).Page ID, Byanyima R, Hosmane S; et al. (2019). "Chronic Pulmonary Aspergillosis Commonly Complicates Treated Pulmonary Tuberculosis With Residual Cavitation". European Respiratory Journal. doi:10.1183/13993003.01184-2018. PMID 30705126.Sehgal IS, Muthu V, Salzer HJF, Agarwal R (2026). "Post-Tuberculosis Lung Disease and Pulmonary Aspergillosis Management: Challenges and Considerations". Expert Review of Anti-Infective Therapy. doi:10.1080/14787210.2026.2631525. PMID 39967172 Check |pmid= value (help).
TB survivors have an estimated standardized mortality ratio of approximately 2.9 compared with the general population, with cardiovascular disease, cancer, and respiratory diseases among the leading causes of post-treatment death.Romanowski K, Baumann B, Basham CA; et al. (2019). "Long-Term All-Cause Mortality in People Treated for Tuberculosis: A Systematic Review and Meta-Analysis". The Lancet Infectious Diseases. doi:10.1016/S1473-3099(19)30309-3. PMID 31530472.
People with prior TB have an approximately 1.6-fold increased risk of all cancers and a 3.2-fold increased risk of lung cancer compared with controls.Luczynski P, Poulin P, Romanowski K, Johnston JC (2022). "Tuberculosis and Risk of Cancer: A Systematic Review and Meta-Analysis". PLoS One. doi:10.1371/journal.pone.0278661. PMID 36584036 Check |pmid= value (help).
Long-term sequelae after pulmonary TB (including cardiopulmonary impairment and chronic respiratory symptoms) are reviewed in narrative and European Respiratory Society publications.Wang J, Yuan B, Fang Y; et al. (2025). "Post-Tuberculosis Morbidities and Their Associated Mortality: Moving From Challenges to Solutions". European Respiratory Review. doi:10.1183/16000617.0148-2025. PMID 40471221 Check |pmid= value (help).Gupte AN, Boisson-Walsh A, Huaman MA; et al. (2026). "Long-Term Sequelae of Pulmonary Tuberculosis: A Narrative Review". Clinical Infectious Diseases. doi:10.1093/cid/ciag123. PMID 40311222 Check |pmid= value (help).
Prognosis
Prognosis by drug susceptibility pattern
Mortality differs substantially by drug susceptibility pattern in treated TB cohorts from high-burden countries.Zürcher K, Ballif M, Fenner L; et al. (2019). "Drug Susceptibility Testing and Mortality in Patients Treated for Tuberculosis in High-Burden Countries: A Multicentre Cohort Study". The Lancet Infectious Diseases. doi:10.1016/S1473-3099(18)30673-X. PMID 30711372.
| Drug susceptibility pattern | Reported mortality (treated cohort)
|
Clinical notes
Prognosis in HIV co-infectionTB in people with HIV has higher risk of disseminated and extrapulmonary disease and higher mortality, especially with advanced immunosuppression. The CD4+ T-lymphocyte count is the strongest predictor of TB-related mortality in people with HIV.Meintjes G, Maartens G (2024). "HIV-Associated Tuberculosis". The New England Journal of Medicine. doi:10.1056/NEJMra2308181. PMID 38281818 Check
 ReferencesShih RD (2025). "A Critical Issue in the Management of Adult Patients Presenting to the Emergency Department With Acute Carbon Monoxide Poisoning". Annals of Emergency Medicine. doi:10.1016/j.annemergmed.2024.12.005. PMID 40118649 Check |
|---|